The deal will give Lyell a dual-targeting CAR-T candidate for blood cancers. Relatedly, Lyell has opted to end development of ...

An agency panel recommended lowering the age for routine vaccination from 65 to 50, boosting the revenue outlook for multiple ...

Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't ...

As Sanofi prepares to halt U.S. marketing of its dengue vaccine in 2026, locally acquired infections in the country are ...

Xavier, who leads biotech venture investing for the big drugmaker, expects an uptick in IPOs as well as renewed interest in ...

Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market ...

Sapient, a leading biomarker discovery organization providing at scale services for multi-omics data generation and analysis, ...

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

With “nerves of steel,” Amgen is getting ready to sell a copycat of Regeneron’s top-selling eye drug Eylea, even as ...

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...

While analysts still see value in Alto’s approach to brain drugmaking, investors may have lost some faith, as the biotech’s ...

Early data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say such ...